By means of
Published
Vancouver, British Columbia–(Newsfile Corp. –September 20, 2022) –WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”), a clinical-stage pharmaceutical company, announces that the Company The Board of Directors (the “Board”) has approved the construction of WPD Pharmaceuticals Sp. zoo. (“WPD Poland”), the Company’s Polish subsidiary increased its capital percentage from PLN 400,000 to PLN 2,100,000, or PLN 1,700,000, by creating PLN 34,000 new equivalent and indivisible percentages with a nominal price of PLN 50 and a nominal price of PLN 1,700,000. WPD Poland’s capital accumulation percentage is the step of the moment in a WPD Poland restructuring plan, which the company announced on February 9, 2022.
Accordingly, on September 14, 2022, the General Shareholders’ Meeting of WPD Poland approved a capital percentage of PLN 400,000 to PLN 2,000. The new percentages will be subscribed and supported through a biotechnology investor until December 31, 2022. The company’s long-term plans include raising capital on the Polish capital market and the WPD Polska directory on the Warsaw Stock Exchange. The implementation of this plan is based on the evolution of the capital market in Europe.
About WPD Pharmaceuticals
WPD is a biotechnology and progression company focused on oncology and virology, that is, the progression of drugs involving biological compounds and small molecules. WPD has nine new applicants for legal drugs in some countries, four of which are in clinical progression. These drug applicants have been studied in medical institutions, and WPD lately maintains ongoing collaborations with Wake Forest University and Poland’s leading hospitals and educational centers.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc. , respectively, granting WPD an exclusive royalty sublicense for certain licensor technologies. , production and sales rights, among others. CNS Pharmaceuticals and Moleculin Biotech’s sublicense territory includes about 29 countries in Europe and Asia, plus Russia, according to the compound.
On behalf of the Board
“Mariusz Olejniczak”
Mariusz OlejniczakCEO, WDP Pharmaceuticals
Contact:
Investor RelationsEmail: [email protected]Tel: 604-428-7050
Website: www. wpdpharmaceuticals. com
Warnings:
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accept the adequacy or accuracy of this release.
This press release comprises s. Forward-looking statements are statements that contemplate activities, events or expansions that the company believes will or possibly will occur in the future, that WPD would particularly benefit from advancing berubicin as a GBM treatment. The forward-looking warnings contained in this news release imply that WPD’s drugs could potentially become new cancer treatments. These forward-looking statements reflect the Company’s existing expectations based on data that must be controlled and are subject to a number of hazards and uncertainties that may also cause actual effects to differ materially from those projected. The factors that could prevent the prospects from being made are that the drug compounds would not provide the expected benefits and we would not expand them further; competition or others would possibly effectively challenge an issued patent and the patent would possibly be revoked; that we are not able to raise enough budget for our research; that we may not qualify for the grants awarded; that our drugs do not provide a positive treatment, or if they do, the side effects are detrimental; the competition would possibly expand more or less expensive drugs; and we may not be able to download regulatory approval for the drugs we expand. The Company assumes no legal responsibility to update them, unless required by applicable law.